To discover

Principal Investigator Marc Therrien

Competitive Advantages

Raf dimer program

BMS_Undisclosed target – Biosensors – Development of a GPCR-3 small molecule antagonist for cardiovascular indications (PAR4 follow up) – Activity 3.1 (GPCR-3) (from october 2016 to may 2017)

BMS_Undisclosed target – Cardiology – Screening for functionally selective GPCR drugs for cardiovascular indications (AT1R) – Activity 2 (GPCR-2) (from may 2017 to sept 2017)

Inhibitors of MAPK pathway PPIs (from sept 2017 to oct  2017)

BMS_Developing novel functionally-selective therapeutics targeting the FPR2 receptor (from oct 2017 to ……)